NuCana (NASDAQ:NCNA) Releases Quarterly Earnings Results, Beats Estimates By $2.18 EPS

NuCana (NASDAQ:NCNA) issued its quarterly earnings results on Thursday. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.65) by $2.18, Zacks reports.

NuCana Trading Up 1.1%

NASDAQ:NCNA traded up $0.01 during trading hours on Friday, reaching $0.94. 10,854 shares of the company traded hands, compared to its average volume of 71,015. The business’s 50-day moving average price is $1.14 and its two-hundred day moving average price is $1.66. NuCana has a 1 year low of $0.88 and a 1 year high of $4.55. The stock has a market capitalization of $3.91 million, a P/E ratio of -0.25 and a beta of 2.39.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of NuCana in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

About NuCana

NuCana plc is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments. The company uses its ProTide technology to create nucleotide analog medicines designed to improve the delivery and activity of existing chemotherapy agents while addressing mechanisms that can limit treatment effectiveness. NuCana’s development portfolio has included NUC-1031, also known as Acelarin, a ProTide form of gemcitabine evaluated in several solid tumors. The company has also advanced NUC-3373, a ProTide-based fluoropyrimidine designed to deliver the active component of 5-fluorouracil, and NUC-7738, an investigational cancer therapy based on a nucleoside analog.